Solange Peters

Solange Peters's AcademicInfluence.com Rankings

Solange Peters

Philosophy

#5050

World Rank

#7763

Historical Rank

Logic

#2392

World Rank

#3376

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Solange Peters Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Solange Peters's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (1839)
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer (2017) (1553)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (2019) (1372)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018) (1327)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer (2017) (1217)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (1102)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (997)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance (2019) (895)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (706)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (671)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (628)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (2019) (627)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (626)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (616)
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. (2013) (567)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. (2017) (563)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (512)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (512)
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study (2020) (419)
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial (2021) (377)
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. (2014) (362)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (355)
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. (2012) (349)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (336)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer (2020) (323)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). (2017) (306)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). (2017) (306)
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (296)
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. (2015) (292)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. (2019) (281)
MET: a promising anticancer therapeutic target (2012) (277)
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial (2015) (269)
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients (2017) (268)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. (2017) (259)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. (2020) (250)
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. (2016) (246)
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. (2016) (246)
TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. (2020) (228)
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. (2014) (223)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. (2019) (211)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (209)
Scientific Advances in Lung Cancer 2015 (2016) (207)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (191)
Brain metastases. (2019) (182)
Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. (2008) (179)
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium (2021) (178)
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. (2017) (172)
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. (2017) (172)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. (2017) (171)
Pulmonary sarcoid-like granulomatosis induced by ipilimumab. (2012) (170)
ALK inhibitors in the treatment of advanced NSCLC. (2014) (170)
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC (2017) (170)
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. (2014) (168)
Corrections to "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (166)
COVID-19 and Cancer: Current Challenges and Perspectives (2020) (160)
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. (2015) (159)
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. (2015) (159)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. (2020) (158)
The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. (2016) (155)
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. (2019) (148)
Brain metastases (2019) (146)
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS (2019) (146)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (145)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. (2018) (144)
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort (2015) (140)
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort (2015) (140)
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (138)
Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. (2000) (134)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (133)
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. (2014) (131)
NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC (2016) (130)
A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. (2019) (125)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers (2018) (124)
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. (2014) (121)
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer (2020) (119)
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression (2013) (118)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. (2019) (118)
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. (2019) (115)
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. (2006) (115)
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study (2020) (107)
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. (2021) (105)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. (2021) (104)
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. (2013) (104)
Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC (2018) (102)
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. (2019) (102)
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers (2016) (102)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee (2020) (97)
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. (2009) (94)
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. (2018) (94)
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2021) (91)
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2021) (91)
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. (2020) (90)
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. (2019) (87)
Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026 (2017) (87)
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer (2016) (86)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. (2017) (85)
Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein (2001) (84)
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 (2021) (83)
Overcoming therapy resistance in EGFR-mutant lung cancer (2021) (83)
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer (2014) (83)
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer (2019) (81)
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial (2021) (80)
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial (2021) (80)
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). (2019) (80)
Challenges in lung cancer therapy during the COVID-19 pandemic (2020) (78)
Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations. (2020) (76)
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (76)
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. (2019) (76)
16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) (2015) (75)
ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC (2018) (74)
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) (2018) (73)
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer (2015) (72)
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy (2020) (72)
Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. (2019) (71)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (70)
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma (2018) (70)
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate (2021) (69)
Current status of immune checkpoint inhibition in early stage NSCLC. (2019) (68)
Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee. (2020) (68)
How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer. (2019) (66)
Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
Optimizing panel-based tumor mutational burden (TMB) measurement. (2019) (65)
Analysis of Natural Variants of the Human Immunodeficiency Virus Type 1 gag-pol Frameshift Stem-Loop Structure (2002) (64)
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. (2021) (63)
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. (2019) (62)
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. (2019) (62)
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program (2018) (61)
Gender Medicine and Oncology: Report and consensus of an ESMO Workshop. (2019) (61)
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. (2011) (58)
Targeted therapy in NSCLC driven by HER2 insertions. (2014) (57)
Clinical Outcome of ALK‐Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co‐Mutations Receiving Tyrosine Kinase Inhibitors (TKIs) (2017) (57)
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non–Small Cell Lung Cancer (2019) (57)
Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts. (2019) (57)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. (2020) (56)
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. (2008) (56)
Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients (2008) (56)
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic (2020) (56)
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration (2020) (53)
Severity of COVID-19 in patients with lung cancer: evidence and challenges (2021) (53)
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. (2010) (48)
OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial (2019) (47)
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. (2021) (47)
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey (2018) (46)
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer (2019) (46)
OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 (2017) (45)
Optimizing panel-based tumor mutational burden (TMB) measurement. (2019) (44)
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. (2021) (44)
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial. (2016) (43)
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study (2020) (42)
Apnea-like suppression of respiratory motion: First evaluation in radiotherapy. (2016) (42)
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. (2017) (42)
Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. (2020) (41)
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors (2019) (40)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (40)
Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. (2020) (40)
Scientific Advances in Thoracic Oncology 2016. (2017) (39)
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). (2014) (39)
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma (2016) (38)
Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. (2017) (38)
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. (2013) (37)
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study (2021) (36)
191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. (2016) (36)
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. (2017) (35)
GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy (2021) (35)
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. (2022) (35)
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline (2021) (34)
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (34)
Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer (2020) (33)
Treatment and detection of ALK-rearranged NSCLC. (2013) (33)
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. (2019) (33)
Neutrophils in the era of immune checkpoint blockade (2021) (33)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis (2019) (33)
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients (2022) (33)
Searching for targets for the systemic therapy of mesothelioma. (2015) (33)
Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. (2007) (33)
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer (2020) (32)
Survival and Local Recurrence After Video-Assisted Thoracoscopic Lung Metastasectomy (2016) (32)
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response. (2021) (31)
Strategies for improving outcomes in NSCLC: a look to the future. (2013) (31)
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. (2019) (31)
IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. (2019) (30)
Report on the status of women occupying leadership roles in oncology (2018) (30)
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC). (2017) (30)
Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters (2014) (30)
Non-genetic evolution drives lung adenocarcinoma spatial heterogeneity and progression. (2021) (30)
Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer. (2013) (29)
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. (2013) (29)
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis (2020) (29)
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence. (2020) (28)
CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC). (2016) (28)
Immune Checkpoint Inhibitors in the Management of Lung Cancer. (2018) (28)
Treatment guidance for lung cancer patients during the COVID-19 pandemic (2020) (27)
Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. (2021) (27)
Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. (2015) (27)
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial (2021) (27)
Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model1 (2014) (27)
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort (2019) (26)
A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial. (2017) (26)
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer (2020) (26)
Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. (2019) (25)
CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC). (2016) (25)
Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives (2013) (25)
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma (2021) (25)
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? (2013) (25)
Gender medicine and oncology: report and consensus of an ESMO workshop. (2019) (24)
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project (2018) (24)
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. (2019) (24)
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer (2019) (24)
P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery (2021) (23)
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial (2017) (23)
LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis (2020) (23)
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (23)
The search for improved systemic therapy of non-small cell lung cancer--what are today's options? (2011) (23)
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial. (2018) (22)
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial (2020) (22)
A standardised , generic , validated approach to stratify the magnitude of clinical bene fi t that can be anticipated from anti-cancer therapies : the European Society for Medical Oncology Magnitude of Clinical Bene fi t Scale ( ESMO-MCBS ) (2015) (22)
Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung (2016) (22)
Treatment of limited disease small cell lung cancer: the multidisciplinary team (2017) (22)
A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors (2016) (22)
FDG‐PET SUV‐max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma (2013) (22)
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer (2017) (21)
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. (2017) (21)
Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer (2020) (21)
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer. (2021) (21)
OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study (2017) (21)
Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs (2010) (20)
Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project. (2021) (20)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. (2021) (20)
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. (2020) (20)
Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study. (2017) (20)
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). (2013) (20)
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. (2020) (19)
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
Genomic Features of Response to Combination Immunotherapy in Lung Cancer. (2018) (19)
Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer (2020) (19)
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD‐L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology (2016) (19)
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient (2019) (19)
Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer (2013) (19)
Impact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome. (2012) (19)
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. (2011) (19)
Genomic Features of Response to Combination Immunotherapy in Lung Cancer. (2018) (19)
Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). (2013) (19)
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. (2015) (18)
Patients with AIDS-defining cancers are not universally screened for HIV: a 10-year retrospective analysis of HIV-testing practices in a Swiss university hospital (2014) (18)
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19). (2020) (18)
Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? (2010) (18)
The METeoric rise of MET in lung cancer (2020) (18)
Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density (2012) (18)
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial (2022) (18)
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study (2022) (18)
KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). (2020) (18)
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (17)
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. (2020) (17)
HIV Testing Practices by Clinical Service before and after Revised Testing Guidelines in a Swiss University Hospital (2012) (17)
Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. (2009) (17)
A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial. (2020) (17)
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study (2020) (17)
The role of radiation therapy in the management of small cell lung cancer (2017) (17)
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer (2019) (17)
Immune checkpoint inhibitors and small cell lung cancer: what's new? (2018) (17)
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). (2020) (17)
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma (2021) (17)
1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study (2017) (17)
Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. (2020) (17)
RANKL signaling sustains primary tumor growth in genetically engineered mouse models of lung adenocarcinoma (2017) (17)
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis (2021) (17)
Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non‐small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices (2017) (16)
The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19 (2021) (16)
Therapeutic advances in non-small cell lung cancer (2011) (16)
Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC) (2015) (16)
Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients. (2020) (16)
Distribution of free and liposomal doxorubicin after isolated lung perfusion in a sarcoma model. (2008) (15)
Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians (2020) (15)
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? (2020) (15)
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? (2020) (15)
Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin. (2009) (15)
Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event? (2012) (15)
P1.04-008 POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC (2017) (15)
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. (2019) (15)
The central region of human immunodeficiency virus type 1 p6 protein (Gag residues S14-I31) is dispensable for the virus in vitro. (2004) (15)
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. (2015) (14)
Solitary choriocarcinoma in the lung. (2010) (14)
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data (2021) (14)
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. (2014) (14)
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long‐Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01) (2019) (14)
Multidisciplinary treatment of lung cancer in older patients: A review. (2019) (14)
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (14)
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long‐Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01) (2019) (14)
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients (2020) (14)
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. (2015) (14)
410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study (2017) (14)
Resection of Skin Metastases from Gastric Carcinoma with Long–Term Follow–Up: An Unusual Clinical Presentation (2004) (13)
1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) (13)
Tumour neoantigen mimicry by microbial species in cancer immunotherapy (2021) (13)
EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372). (2016) (13)
LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19) (2020) (13)
Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. (2019) (13)
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy (2018) (13)
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non‐small‐Cell Lung Cancer Receiving Erlotinib Treatment (2017) (13)
Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. (2019) (13)
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer (2021) (12)
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study (2021) (12)
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) (2020) (12)
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology (2021) (12)
Radiomics Feature Activation Maps as a New Tool for Signature Interpretability (2020) (12)
LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743 (2021) (12)
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer (2013) (11)
Going beyond EGFR. (2012) (11)
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (2022) (11)
Acceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration (2018) (11)
Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study (2017) (11)
Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. (2022) (11)
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects (2022) (11)
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small‐cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial (2017) (11)
Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network (2021) (11)
Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study. (2015) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Brief report "Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis". (2020) (11)
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small‐cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial (2017) (11)
1195OFINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (10)
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel (2021) (10)
ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. (2022) (10)
Lung Cancer in the Canton of St. Gallen, Eastern Switzerland: Sex-Associated Differences in Smoking Habits, Disease Presentation and Survival (2009) (10)
STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT (2016) (10)
Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. (2014) (10)
1195OFINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (10)
Feasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study. (2017) (10)
Successes and limitations of targeted cancer therapy (2014) (10)
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. (2020) (10)
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery (2019) (10)
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. (2020) (10)
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC. (2019) (10)
EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report (2013) (10)
PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. (2019) (9)
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). (2021) (9)
First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743 (2020) (9)
Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested? (2013) (9)
The role of advanced nursing in lung cancer: A framework based development. (2015) (9)
Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. (2008) (9)
Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients – evaluation of outcome and prognostic factors: A retrospective multicenter study (2021) (9)
2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
Photodynamic Therapy Enhances Liposomal Doxorubicin Distribution in Tumors during Isolated Perfusion of Rodent Lungs (2011) (9)
LBA37_PRNEOADJUVANT CHEMOTHERAPY AND EXTRAPLEURAL PNEUMONECTOMY (EPP) OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) WITH OR WITHOUT HEMITHORACIC RADIOTHERAPY: FINAL RESULTS OF THE RANDOMIZED MULTICENTER PHASE II TRIAL SAKK17/04 (2014) (9)
Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study. (2019) (9)
Management of Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Single-Center Experience (2013) (8)
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. (2020) (8)
A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. (2018) (8)
Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort. (2021) (8)
Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I. (2016) (8)
EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice? (2012) (8)
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study. (2020) (8)
Use of second-line biochemical and susceptibility tests for the differential identification of coryneform bacteria (1998) (8)
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial (2022) (8)
Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland. (2013) (8)
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade. (2019) (8)
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer (2015) (7)
Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer (2011) (7)
Thymoma with molecularly verified “conversion” to T lymphoblastic leukemia/lymphoma over 9 years (2013) (7)
Tobacco-related cancer mortality: projections for different geographical regions in Switzerland. (2013) (7)
JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial (2017) (7)
Thalidomide in small cell lung cancer: wrong drug or wrong disease? (2009) (7)
Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I (2014) (7)
Consensus Conference on Lung Cancer : early-stage non-small-cell lung cancer consensus on diagnosis , treatment and follow-up (2014) (7)
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE) (2022) (7)
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2) (2021) (7)
P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy (2018) (6)
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. (2022) (6)
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. (2020) (6)
Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data (2021) (6)
The Promising Evolution of Targeted Therapeutic Strategies in Cancer. (2021) (6)
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis (2022) (6)
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. (2018) (6)
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling (2017) (6)
Gender gap: surveying the world for tomorrow (2020) (6)
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. (2016) (6)
Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies (2020) (6)
Emerging Options After Progression During Crizotinib Therapy. (2016) (6)
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience (2020) (6)
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC (2019) (6)
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort (2020) (6)
Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. (2018) (6)
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. (2021) (6)
A Phase I study of men-10755 in patients with a solid tumor as a shorti.v. infusion given once every 3 weeks (1999) (6)
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. (2021) (6)
Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach. (2011) (6)
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2 (2020) (6)
Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys. (2018) (6)
Computer‐Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort (2018) (6)
MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry (2018) (5)
The place of radiotherapy in the palliative management of NSCLC (2011) (5)
Surgical Resection of Isolated Adrenal Metastases in Patients with Non-Small Cell Lung Cancer: A Single-Institution Experience and Review of the Literature (2011) (5)
1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial (2020) (5)
EML4-ALK Variant Affects ALK Resistance Mutations. (2018) (5)
Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer (2017) (5)
Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool (2020) (5)
Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study. (2018) (5)
Treatment of pleural malignancies by photo‐induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities (2015) (5)
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry (2022) (5)
Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry (2020) (5)
Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC. (2018) (5)
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma (2021) (5)
Imaging Features of Pulmonary Immune-related Adverse Events. (2021) (5)
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab (2021) (5)
EML4-ALK Variant Affects ALK Resistance Mutations. (2018) (5)
ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)–naive, advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) (2016) (4)
SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer (2016) (4)
1255TiP CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC) (2020) (4)
98O_PRTARGETED THERAPY FOR BRAF-MUTANT LUNG CANCER: RESULTS FROM THE EUROPEAN EURAF COHORT STUDY (2015) (4)
Lung cancer: How much platinum-based chemotherapy is enough in NSCLC? (2015) (4)
The ESMO guideline strategy: an identity statement and reflections on improvement. (2015) (4)
Development and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: The Symptom Navi© Programme. (2019) (4)
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08) (2019) (4)
Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade (2022) (4)
Implementation of the Symptom Navi © Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi© Pilot Study) (2019) (4)
Early discharge after thoracoscopic anatomical pulmonary resection for non-small-cell lung cancer. (2021) (4)
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients (2021) (4)
Extrapleural pneumonectomy with venous confluence resection for stage IVA thymic tumors. (2011) (4)
Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. (2022) (4)
Unmet supportive care needs of lung cancer patients during the chemotherapy phase: A descriptive study (2012) (3)
Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases (2022) (3)
[VATS lobectomy for early-stage primary lung cancer]. (2012) (3)
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer. (2019) (3)
A neutrophil response linked to tumor control in immunotherapy (2023) (3)
Seeking New Approaches to Patients With Small Cell Lung Cancer. (2016) (3)
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events (2022) (3)
[Small-cell lung cancer: management and novelties]. (2020) (3)
PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive‐Stage SCLC After First‐Line Chemotherapy: Topic: Medical Oncology (2016) (3)
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials (2022) (3)
[Management pulmonary metastases: when operate?]. (2012) (3)
Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (2018) (3)
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer. (2019) (3)
Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer. (2014) (3)
Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer (2015) (3)
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. (2023) (3)
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital (2022) (3)
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging (2021) (3)
Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets (2021) (3)
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. (2016) (3)
OncoAlert Round Table Discussions: The Global COVID-19 Experience (2021) (3)
New therapeutic strategies in lung cancers (2015) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis. (2020) (2)
Patients' experiences with cancer care in Switzerland: Results of a multicentre cross‐sectional survey (2022) (2)
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis (2022) (2)
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study (2022) (2)
Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial. (2019) (2)
Coexistence of multiple escape mechanisms in a BRAFV600E-mutated cutaneous melanoma treated with vemurafenib. (2013) (2)
1376TiPPhase III study of atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with treatment-naive advanced, recurrent or metastatic NSCLC unsuitable for platinum (plat)-based chemo (2017) (2)
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial (2023) (2)
The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. (2013) (2)
Non-small cell lung cancer, early stage (2012) (2)
Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up† (2015) (2)
Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. (2020) (2)
Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. (2021) (2)
Pilot Testing of a Nurse-Led Basic Symptom Self-management Support for Patients Receiving First-Line Systemic Outpatient Anticancer Treatment (2021) (2)
Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors (2022) (2)
Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib (2014) (2)
Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC (2021) (2)
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves (2022) (2)
The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (2019) (2)
Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC. (2019) (2)
Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project (2015) (2)
Minus Times Minus Equals Plus. (2022) (2)
Personalized Treatment of Advanced Non-small Cell Lung Cancer: EGFR Tyrosine Kinase Inhibitors as a Standard of Care (2014) (2)
Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out. (2014) (2)
Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. (2022) (2)
1334TiPRANDOMISED, MULTICENTRE, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VS CRIZOTINIB IN TREATMENT-NAïVE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NSCLC (ALEX STUDY). (2014) (2)
MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers (2017) (2)
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report (2022) (2)
Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer. (2014) (1)
[Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]. (2021) (1)
Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. (2017) (1)
[Lung cancer screening: what can we tell our patients while we await a screening program ?] (2020) (1)
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases (2021) (1)
Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study (2021) (1)
EP-1910 CT image standardization is superior to larger but heterogeneous datasets for robust radiomic models (2019) (1)
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study. (2015) (1)
Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary (2020) (1)
3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project (2015) (1)
Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study (2017) (1)
[Is prescription of a therapy costing 150,000 CHF reasonable?]. (2015) (1)
Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer (2013) (1)
[Lung cancer screening in Switzerland : Who ? How ? When ?] (2020) (1)
P83.02 Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study (2021) (1)
Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras–Raf–MEK–ERK pathway (2011) (1)
A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A. (2018) (1)
Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports (2022) (1)
2861 Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC) (2015) (1)
MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09) (2017) (1)
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment (2018) (1)
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival (2021) (1)
P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC (2017) (1)
557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial (2020) (1)
Personalized management for non-small-cell lung cancer (2011) (1)
Current and future developments of immunotherapy in lung cancer (2018) (1)
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma (2022) (1)
Setting the Benchmark for KRASG12C -Mutated NSCLC. (2022) (1)
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study (2023) (1)
731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001) (2022) (1)
First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer (2022) (1)
Extended resection for potentially operable stage III NSCLC patients after neoadjuvant treatment (2022) (1)
Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015 (2018) (1)
The French initiative paves the way: routine molecular profiling of advanced non-small-cell lung cancer fights inequalities in access to molecular targeted therapy and improves patient outcome (2016) (0)
Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland (2013) (0)
[Advances in Oncology 2019]. (2020) (0)
Symptom Navi© Program: Training nurses to facilitate cancer patients’ self-managent of symptoms within a structured program (2018) (0)
P3.04-009: Evaluation of RT-PCR Methodology for ALK Assessment in Patients with NSCLC in Europe: Results from the ETOP Lungscape Project (2015) (0)
Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss cohort study. (2018) (0)
ETOP activity in the field of biomarkers and predictors (2012) (0)
Randomized trial of a 3-fold dose intensification of Ifosfamide, Carboplatin, Etoposide chemotherapy for the treatment of small cell lung cancer: P1-221 (2007) (0)
[The role of EGFR in non-small cell lung carcinoma]. (2009) (0)
ESMO-ESP - Molecular diagnostics for personalized cancer treatment (2012) (0)
[Oncology: navigating the COVID-19 Pandemic and Steer the Course]. (2020) (0)
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer (2014) (0)
Band 32, Heft 10, October 2009 (2009) (0)
[Postoperative radiation therapy in lung carcinom]. (2014) (0)
Advances in Radiotherapy for Locally Advanced NSCLC (2015) (0)
68P Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743) (2020) (0)
PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09) (2017) (0)
Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial (2016) (0)
Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial (2016) (0)
Immunotherapy-based combinations in metastatic NSCLC. (2023) (0)
PO-1803 Voxel-wise quantification of anatomical tumor lung location is associated with overall survival (2021) (0)
ES09.03 Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy (2021) (0)
[Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]. (2010) (0)
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling (2017) (0)
Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies (2022) (0)
Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives (2023) (0)
[2020 oncology update]. (2021) (0)
CN38 Implementing a nursing symptom self-management intervention: The Symptom Navi Program (2020) (0)
Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). (2010) (0)
31PTargeted therapy for patients with ALK positive NSCLC: Results from the transalpine cohort (2017) (0)
32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis (2022) (0)
- mutated cutaneous melanoma successfully rechallenged after initial progression (2013) (0)
P2.12-21 Outcomes with Immune Checkpoint Inhibitors (ICI) for Relapsed Small Cell Lung Cancer (SCLC) in a Swiss Cohort (2019) (0)
Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC) (2015) (0)
P1.02-025 Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project: Topic: Driver Genes in NSCLC, Resistance, and Other (2017) (0)
Molecular profiling of non-small cell lung cancer by histologic subtype. (2014) (0)
EJ-4Immunotherapy for lung cancer (2015) (0)
2807 Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC) (2015) (0)
1264P Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial (2021) (0)
80P MANAGEMENT OF ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: A SINGLE CENTRE EXPERIENCE (2013) (0)
Gender- specificaspectsof epidemiology,moleculargeneticsand outcome:lungcancer (2020) (0)
EGFR Exon-Level Biomarkers Of The Response To Bevacizumab-Erlotinib (BE) In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - A Translational Substudy Of SAKK 19/05 (2012) (0)
Addition of cetuximab to ﬁrst-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis (2011) (0)
Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib. (2022) (0)
Adequacy of video-assisted mediastinal lymphadenectomy for stage I non-small cell lung cancer (2013) (0)
The Lungscape Project. (2012) (0)
Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data (Preprint) (2021) (0)
Characterisation of rare haematological immune-related toxicities. (2019) (0)
1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE) (2021) (0)
HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors – a case report (2021) (0)
Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer. (2014) (0)
1199PDPREVALENCE AND CLINICAL OUTCOMES FOR PATIENTS WITH MET PROTEIN EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN EUROPE: RESULTS FROM THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT. (2014) (0)
1393PChemotherapy in advanced cancer patients with poor performance status (PS) initiated in an integrated oncology and palliative care (PC) setting: an observational comparative study (2017) (0)
ES22.02 A Milestone in Locally Advanced NSCLC (2019) (0)
PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI) (2017) (0)
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma (2016) (0)
6603 POSTER Sequential or concomitant chemotherapy and 3D conformal radiation therapy with dose-volume histogram assessment in limited disease small cell lung cancer (2007) (0)
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer — A Multicentre Single-Arm Phase II Trial (2021) (0)
P2.07-012 Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC) (2017) (0)
69INDEFINING THE ROLE OF TARGETED THERAPIES IN EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (0)
PET Radiomics Model Based on Multi-Centre Imaging Data of SAKK 16/00 to Predict Event-Free Survival in Locally Advanced Non-Small Cell Lung Cancer (2019) (0)
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) (2016) (0)
[Occupational cancers: essentials for the general practioners]. (2022) (0)
Contents Vol. 34, 2011 (2011) (0)
EP-1074 HELICAL TOMOTHERAPY IN THE TREATMENT OF ANAL CANCER: THE LAUSANNE EXPERIENCE (2012) (0)
Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. (2019) (0)
1389PDPrognostic impact of drug interactions in patients with advanced cancer (2017) (0)
Call for a holistic framework for cancer immunotherapy (2022) (0)
Strategy on Patients with EGFR Mutation (2015) (0)
195PPROSPECTIVE EVALUATION OF CIRCULATING VEGF IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH BEVACIZUMAB, PEMETREXED AND CISPLATIN IN THE TRIAL SAKK19/09. (2014) (0)
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer — A Multicentre Single-Arm Phase II Trial (2021) (0)
463 Vibostolimab plus pembrolizumab with/without docetaxel vs docetaxel in NSCLC after platinum chemotherapy and immunotherapy (2021) (0)
Abstract CT080: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) in 1L metastatic NSCLC: Outcomes by blood tumor mutational burden (bTMB) in POSEIDON (2023) (0)
P09.18 COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT) (2021) (0)
Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON. (2022) (0)
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance (2022) (0)
[The new management options for lung cancer in the immunotherapy era]. (2019) (0)
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC? (2022) (0)
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. (2018) (0)
Seeking New Approaches to Patients With Small Cell Lung Cancer. (2016) (0)
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. (2022) (0)
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. (2022) (0)
[Oncology: what's new in 2022]. (2023) (0)
ESMO-ESP Joint Symposium: Molecular diagnostics for personalized cancer treatment 116IN NEXT GENERATION SEQUENCING IN THE CONTEXT OF CURRENT CLINICAL PRACTICE: IMPLEMENTATION AND CHALLENGES (2012) (0)
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas. (2023) (0)
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries (2022) (0)
non-small cell lung cancer, early stage 1179O THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT: A WAY TO BRIDGE NON-SMALL CELL LUNG CANCER MOLECULAR CHARACTERISTICS AND CLINICAL DATA (2012) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST). (2022) (0)
EJS-1 Flexibility to sustain solidity. Addressing new vulnerabilities in cancer at the time of COVID-19 (2022) (0)
IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen (2022) (0)
COVID-19 in cancer patients: Update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases (2023) (0)
Hot-to-Global Volume Ratio (HGVR): A novel tool to predict PD-L1 tumoral expression and outcome in NSCLC patients treated with checkpoint inhibitors using standard FDG PET/CT (2018) (0)
RANKing lung cancer bone metastasis (2012) (0)
Molecular Typing of Lung Cancer: More Pieces to the Puzzle (2012) (0)
P1.08-065 Resection of Isolated Brain Metastasis Improves Outcome of Non-Small-Cell Lung Cancer (NSCLC) Patients: A Retrospective Multicenter Study: Topic: Surgery for Locally Advanced and Advanced NSCLC (2017) (0)
Establishment of CORONET: COVID-19 Risk in Oncology Evaluation Tool to Identify Cancer Patients at Low Versus High Risk of Severe Complications of COVID-19 Infection Upon Presentation to Hospital (2021) (0)
[Targeted therapies and non-small cell carcinomas : novelties]. (2022) (0)
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer (2015) (0)
Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1. (2023) (0)
Systemic therapy of neuroendocrine tumors of the lung (2012) (0)
Histo- and molecular pathology of lung cancer (2012) (0)
A period of fears and challenges: Toward a better world? (2020) (0)
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (0)
An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19). (2022) (0)
A differential process mining analysis of COVID-19 management for cancer patients (2022) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
[Oncology, what's new in 2018]. (2019) (0)
ES02.05 Structured Approach For Developing and Implementing and Advanced Practice Nursing Role in Lung Cancer (2018) (0)
Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage. (2019) (0)
small improvement over best supportive care in clinical outcome should be expected. (2014) (0)
Institutional report - Experimental Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of freeyliposomal doxorubicin , (2009) (0)
SY15-1The European Thoracic Oncology Platform (ETOP) (2015) (0)
Abstract 3093: Quantifying the confounders of panel-based tumor mutational burden (TMB) measurement (2020) (0)
Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival (2020) (0)
Sequential or Concomitant Chemotherapy and 3D Conformal Radiation Therapy With Dose-Volume Histogram Assessment in Limited Disease Small Cell Lung Cancer (2007) (0)
MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics (2021) (0)
ID: 81 (2015) (0)
CT image standardization is superior to larger but heterogeneous data for robust radiomic models. (2019) (0)
PO-1563: New voxel-based approach to study the relation of tumor location and survival in NSCLC (SAKK-16/00) (2020) (0)
Feasibility of advanced practice nurse in lung cancer consultations during early treatment: a phase II study (2017) (0)
P14.03 Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy (2021) (0)
Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials. (2018) (0)
Immunotherapy Is Evolving and Promising for Lung Cancer (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Solange Peters?

Solange Peters is affiliated with the following schools:

University of Lausanne
Complutense University of Madrid
University of Bern

Solange Peters's Academic­Influence.com Rankings

Why Is Solange Peters Influential?

Solange Peters's Published Works

Published Works

What Schools Are Affiliated With Solange Peters?

Solange Peters's AcademicInfluence.com Rankings